Bortezomib and Rituximab for Patients With Waldenstrom's Macroglobulinemia
Status:
Active, not recruiting
Trial end date:
2021-02-28
Target enrollment:
Participant gender:
Summary
The main goal of this clinical research study is to learn if Velcade ® (bortezomib) given
with rituximab can help to control WM. This drug combination will allow researchers to
collect your stem cells in case it is possible to transplant the stem cells as treatment if
your WM gets worse. Researchers will also look at the safety and tolerability of this drug
combination followed by treatment with other drug combinations.